Related Experiment Video
Updated: Jun 5, 2026
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
Published on: April 4, 2019
Respiratory syncytial virus disease: update on treatment and prevention
1Winthrop University Hospital, Mineola, NY, USA. lkrilov@winthrop.org
Insights
Respiratory syncytial virus (RSV) causes over 100,000 infant hospitalizations annually in the US. Current treatments are mainly supportive, with limited benefits from existing drugs and prophylaxis options.
Area of Science:
- Pediatric Infectious Diseases
- Virology
- Respiratory Medicine
Background:
- Respiratory syncytial virus (RSV) is a major cause of severe respiratory infections in infants and young children.
- RSV leads to over 100,000 US hospitalizations annually, predominantly in infants under one year old.
- Globally, RSV causes an estimated 160,000 to 600,000 deaths each year, with high-risk groups including premature infants and those with underlying health conditions.
Purpose of the Study:
- To review the current landscape of respiratory syncytial virus (RSV) disease.
- To evaluate the efficacy of existing treatments and prophylaxis for RSV.
- To discuss future directions in RSV therapeutics and prevention.
Main Methods:
- Literature review of studies on RSV epidemiology, treatment, and prevention.
- Analysis of clinical trial data for bronchodilators, corticosteroids, montelukast, ribavirin, and palivizumab.
- Discussion of emerging therapeutic strategies and vaccine development.
Main Results:
- Supportive care remains the primary treatment for RSV infections.
- Bronchodilators, corticosteroids, and montelukast have shown no conclusive clinical benefit.
- Ribavirin offers marginal benefit and is not routinely recommended; palivizumab is effective for prophylaxis in high-risk infants but cost-effectiveness needs definition.
Conclusions:
- Effective treatments for RSV disease are limited, necessitating further research.
- Future strategies may involve advanced monoclonal antibodies like motavizumab, novel antivirals, and anti-inflammatory agents.
- While RSV vaccines are under development, they are not expected imminently.
Abstract:
Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections in infants and young children, accounting for more than 100,000 hospitalizations per year in the USA. The majority of hospitalizations occur in infants less than 1 year of age. Worldwide, RSV is associated with an annual mortality rate of 160,000-600,000 deaths. Premature infants, and infants with congenital heart disease, neuromuscular disease, structural airway abnormalities and immunodeficiencies are at increased risk for severe RSV disease. Despite the magnitude of RSV disease, treatment remains primarily supportive. Trials of bronchodilators, corticosteroids and montelukast have not demonstrated conclusive clinical benefit. The antiviral drug ribavirin has demonstrated only marginal clinical benefit and is not routinely indicated in treatment of RSV disease. Palivizumab is beneficial in prophylaxis for infants at high-risk for severe RSV infection although optimal indications based on cost-effectiveness considerations have not been defined. Future directions in treatment and prevention of RSV infections likely include the second-generation monoclonal antibody motavizumab, more potent antiviral compounds and more unique anti-inflammatory agents. Vaccination against RSV is in development but not eminent.
More Related Videos
Related Concept Videos
01:29Respiratory Syncytial Virus Disease
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:31Common Respiratory Disorders
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: